---
title: "Acumen Pharmaceuticals IncQ) expected to post a loss of 52 cents a share - Earnings Preview"
description: "Acumen Pharmaceuticals IncQ) is expected to report a loss of 52 cents per share for the quarter ending June 30, 2025, with no change in quarterly revenue. Analysts have a strong buy rating on the stoc"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252265648.md"
published_at: "2025-08-08T15:32:05.000Z"
---

# Acumen Pharmaceuticals IncQ) expected to post a loss of 52 cents a share - Earnings Preview

> Acumen Pharmaceuticals IncQ) is expected to report a loss of 52 cents per share for the quarter ending June 30, 2025, with no change in quarterly revenue. Analysts have a strong buy rating on the stock, with a median 12-month price target of $10.00, significantly above its last closing price of $1.42. The mean earnings estimate has risen by 15.3% in the last three months. Previous quarterly performances show a trend of missed estimates.

-   Acumen Pharmaceuticals Inc (ABOS.OQ) (ABOS.O) is expected to

show no change in quarterly revenue when it reports results on August 12 for the period ending June 30 2025

-   ​LSEG’s mean analyst estimate for Acumen Pharmaceuticals Inc is for a loss of 52 cents per share.
-   The current average analyst rating on the shares is “strong buy” and the breakdown of recommendations is 6 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.”
-   The mean earnings estimate of analysts had risen by about 15.3% in the last three months. ​
-   Wall Street’s median 12-month price target for Acumen Pharmaceuticals Inc is $10.00, about 85.8% above its last closing price of $1.42 Previous quarterly performance (using preferred earnings measure in US dollars). ​

### QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

### ENDING ARTESTIMAT ESTIMATE MET, SE %

### E® MISSED

Mar. 31 2025 -0.41 -0.45 -0.48 Missed -5.7

Dec. 31 2025 -0.48 -0.62 Missed -29.2

Sep. 30 2024 -0.41 -0.36 -0.50 Missed -37​

Jun. 30 2024 -0.28 -0.28 -0.34 Missed -21.4

​​Mar. -0.26 -0.26 -0.25 Beat 3.8

31 2024

Dec. 31 2023 -0.30 -0.26 -0.28 Missed -7.7​

Sep. 30 2023 -0.27 -0.27 -0.24 Beat 9.8

Jun. 30 2023 -0.34 -0.35 -0.28 Beat 19.1

This summary was machine generated August 8 at 15:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

### Related Stocks

- [ABOS.US - Acumen Pharmaceuticals](https://longbridge.com/en/quote/ABOS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Acumen Pharmaceuticals Chief Legal Officer Derek Meisner Reports Sale of Common Shares | Derek Meisner, Chief Legal Officer of Acumen Pharmaceuticals Inc., reported the sale of common shares of the company. Th | [Link](https://longbridge.com/en/news/272332808.md) |
| Acumen Pharmaceuticals Showcases Advances in Alzheimer’s Drug Pipeline Targeting Toxic Amyloid Beta Oligomers | Acumen Pharmaceuticals Inc. has presented advancements in its Alzheimer’s drug pipeline, focusing on Sabirnetug (ACU193) | [Link](https://longbridge.com/en/news/272279073.md) |
| Acumen Pharmaceuticals Unveils Enhanced Brain Delivery Technology for Alzheimer’s Antibody in Phase 2 Trial | Acumen Pharmaceuticals announced at the CTAD conference the development of enhanced brain delivery technology for Alzhei | [Link](https://longbridge.com/en/news/268259922.md) |
| Y Intercept Hong Kong Ltd Acquires New Shares in Acumen Pharmaceuticals, Inc. $ABOS | Y Intercept Hong Kong Ltd acquired 250,848 shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) in Q2, valued at approxi | [Link](https://longbridge.com/en/news/265158253.md) |
| Bank of America Securities Remains a Buy on Acumen Pharmaceuticals (ABOS) | Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Acumen Pharmaceuticals with a price target  | [Link](https://longbridge.com/en/news/266367832.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
